Norstella appoints Kris Joshi as CEO to drive next phase of growth
July 10, 2025Business Services, Consultancy CEO, Corporate, HealthTech, Norstella
Pharma intelligence solutions provider, Norstella, has appointed health-tech leader, Kris Joshi, as its new chief executive officer (CEO) with former …
Amarna Therapeutics and NorthX Biologics collaborate to advance gene therapy for type 1 diabetes
July 10, 2025Mergers and Acquisitions, Research and Development Amarna Therapeutics, Diabetes, Immunology, NorthX Biologics, Type 1 diabetes, gene therapy, immune-mediated diseases
Amarna Therapeutics and NorthX Biologics have finalised an agreement to accelerate the development of Nimvec AM510, a gene therapy targeting …
Eppendorf Award for Young European Investigators 2025 awarded to neuroscientist Varun Venkataramani
July 10, 2025Medical Communications, Medical/ Scientific Writing, Research and Development Neurology, Oncology
Varun Venkataramani, of Heidelberg University Hospital, Germany, has been awarded the 2025 Eppendorf Award for Young European Investigators for his …
First malaria medicine for infants under 4.5kg receives approval
July 9, 2025Medical Communications, Research and Development Coartem Baby, Infections and infestations, Medicines for Malaria Venture, Novartis, Paediatrics, Swissmedic, malaria
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine for newborns and young infants. …
First adult in the UK given new treatment for type 1 diabetes
July 9, 2025The first adult in the UK to trial Tepilzumab for type 1 diabetes has started treatment at the Royal Devon …
Richard Philipson appointed as chief medical officer of Hansa Biopharma
July 9, 2025Research and Development Hansa Biopharma, Immunology, chief medical officer, immunology
Hansa Biopharma has announced that Richard Philipson has been appointed chief medical officer, effective 14 July. Philipson will join the …
Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy
July 9, 2025Research and Development Ciloa, Diabetes, France 2030, Obesity, adiponectin, funding, obesity, type 2 diabetes
French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its lead candidate, APN-sEV, targeting obesity …
Duke Street Bio receives FDA fast track designation for brain metastases treatment
July 8, 2025Medical Communications, Research and Development Duke Street Bio, Oncology, US Food and Drug Administration, brain metastases, breast cancer, fast track designation
Duke Street Bio, a biotech company based in London, UK, has announced that the US Food and Drug Administration (FDA) …
SMC recommends Eladynos for postmenopausal osteoporosis in Scotland
July 8, 2025Medical Communications, Research and Development Musculo-skeletal disorder, NHS, Scottish Medicine Consortium, Theramex, clinical trials, osteoporosis, postmenopause
Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for NHS use …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
July 8, 2025Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …
HeartBeat.bio and biotx.ai partner to develop new drugs for heart failure
July 7, 2025Mergers and Acquisitions, Research and Development AI, Cardiology, HeartBeat.bio, biotx.ai, heart failure
HeartBeat.bio and biotx.ai have entered a partnership to accelerate heart failure drug discovery by combining AI-driven genetics with human cardiac …
T-cell therapy – the evolution of cancer treatments
July 7, 2025CERo therapeutics, Cancer, T cell, immunotherapy
The current forms of immunotherapy, how T cell therapy works and what the future holds
Purpose and people: the enduring power of brand and the evolution of employer identity
July 7, 2025Branding, Business Services, Corporate Branding, Medical Communications, Sales and Marketing AstraZeneca, Identity, Inclusion, The Caffeine Partnership, benenden health, branding
Two decades ago, terms like purpose and people were rarely at the forefront of branding conversations. The focus was on …
The Problem of Endometriosis in the UK
July 7, 2025Research and Development NHS, Obstetrics & Gynaecology, Pain, Reproductive health, Theramex, endometriosis, gynaecology
When did we decide it was an acceptable condition of womanhood in the UK to live with chronic pain?
Five facts about UV exposure and sun safety
July 7, 2025Medical Communications Dermatology, Five Facts, Oncology, Skin, melanoma, skincare
1We can acclimatise to UV exposure. For example, we’re more likely to burn if there’s a sunny spell earlier in …
LEO Pharma appoints Helle Hedegaard Juhl as EVP of global people & corporate affairs
July 7, 2025Manufacturing and Production Dermatology, Helle Hedegaard Juhl, LEO Pharma, Skin, dermatology
Danish dermatology company, LEO Pharma, announced the appointment of new executive vice president (EVP) of global people and corporate affairs, …
Mallia strengthens its advisory board as it accelerates hair loss treatment
July 7, 2025Manufacturing and Production Dermatology, Skin, biopharma, dermatology, hair loss, mallia
German dermatology company, Mallia Innovations, has appointed Jens Holstein, Alexandra Ogilvie and Ulrich Dauer to its advisory board, strengthening its …
FDA grants accelerated approval for advanced non-small cell lung cancer treatment
July 4, 2025Medical Communications, Research and Development Breakthrough Therapy Designation, Oncology, US Food and Drug Administration, Zegfrovy, clinical trial, non-small cell lung cancer, priority review
The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy (sunvozertinib) for the treatment of …
The quiet crisis: why medicines operations matter more than ever in the ICB era
July 4, 2025Business Services, Market Access Gateway to Local Adoption, Integrated Care Board, NHS, Primary Care Networks, Visions4Health
In the second of the Gateway to Local Access series, Vision4Health caught up with Dr Graham Duce, ICB GP Prescribing …
Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment
July 4, 2025Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer
Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
